IPP Bureau
AIC-CCMB signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India
By IPP Bureau - April 19, 2024
Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform
PharmaLytica 2024 to draw 200+ exhibitors
By IPP Bureau - April 19, 2024
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome
By IPP Bureau - April 19, 2024
Around 7% of the Indian population suffers from IBS
Biocon inks agreement for Ozempic commercialization in Brazil with Biomm
By IPP Bureau - April 19, 2024
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Jubilant Pharmova’s Roorkee unit gets VAI status
By IPP Bureau - April 18, 2024
FDA has concluded that this inspection is 'closed'
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
By IPP Bureau - April 17, 2024
Submission based on results from pivotal phase III trial showing all primary endpoints met
Caplin Steriles gets USFDA approval for Ofloxacin ophthalmic solution
By IPP Bureau - April 17, 2024
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
USFDA grants ODD to NM5072 for treatment of Paroxysmal Nocturnal Hemoglobinuria
By IPP Bureau - April 17, 2024
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
AbbVie announces late-breaking data at AAN supporting efficacy of Atogepant for preventive treatment of migraine
By IPP Bureau - April 17, 2024
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
AstraZeneca’s Imfinzi plus chemotherapy doubled overall survival rate for patients with advanced biliary tract cancer
By IPP Bureau - April 17, 2024
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Alvotech and Teva get US FDA approval of Selarsdi
By IPP Bureau - April 17, 2024
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Positive data for Roche multiple sclerosis injection
By IPP Bureau - April 17, 2024
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Cipla Health strengthens its play in beauty and personal care
By IPP Bureau - April 16, 2024
CHL is strengthening its play in the fast-growing beauty and personal care sector
Ami Organics accredited Gold Medal by EcoVadis
By IPP Bureau - April 16, 2024
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
Moderna pauses plan to build mRNA manufacturing facility in Kenya
By IPP Bureau - April 16, 2024
The demand in Africa for COVID-19 vaccines has declined
